Minimally invasive device reduces intraocular pressure for adults with open angle glaucoma
ATLANTA–(BUSINESS WIRE)–Georgia Eye Partners is proud to share that Dr. Parul Khator has become the first eye surgeon in Georgia to utilize the iTrack Advance Canaloplasty Device, a minimally invasive glaucoma surgical device (MIGS) used to reduce intraocular pressure (IOP) in adult patients with primary open-angle glaucoma. The device offers a more efficient glaucoma procedure for patients and surgeons, and can be used standalone or in combination with cataract surgery to help control a glaucoma patient’s eye pressure while lessening their medication burden.
“I am constantly looking for minimally invasive treatment options for my patients that can deliver good results with less risk,” said Dr. Parul Khator, Georgia Eye Partners ophthalmologist and glaucoma specialist. “I personally like the low inflammation profile of this procedure and the device provides me greater visibility and control during surgery.”
Glaucoma, a leading cause of blindness and visual impairment in the U.S., encompasses a group of diseases damaging the optic nerve due to increased eye pressure, potentially caused by infection, injury, blocked vessels, or inflammation. Early-stage glaucoma often lacks symptoms, but as it advances, patients might notice peripheral vision loss, sudden eye pain, headaches, blurred vision, or halos around lights.
First introduced into the U.S. market in 2008, canaloplasty is a stent-free, minimally invasive glaucoma surgery (MIGS) that works with patient physiology to reduce intraocular pressure in glaucoma patients.
Specifically, canaloplasty uses an approach akin to angioplasty to treat blockages in all parts of the eye’s drainage channel, referred to as the conventional outflow pathway – trabecular meshwork, Schlemm’s canal and collector channels – to improve the physiologic outflow of aqueous humor. This contrasts with other MIGS procedures, which mechanically alter the outflow of aqueous humor via a stent or tissue removal.
Georgia Eye Partners remains committed to serving patients throughout Greater Atlanta and Georgia by implementing the latest and greatest advanced glaucoma technologies and procedures.
About Georgia Eye Partners
Georgia Eye Partners is a group practice of ophthalmologists and optometrists committed to providing premier medical and surgical specialty eye care to patients in the Metro Atlanta and North Georgia region, with seven offices in Decatur, Downtown Decatur, Johns Creek, Northside, Emory Midtown, Woodstock, Snellville and North Brookhaven areas. Our services range from disease-specific medical exams to complex specialty surgical care and our outpatient surgery center features state-of-the-art equipment and accreditation from the American Association for Accreditation of Ambulatory Surgery Facilities (AAAASF). To learn more about us, visit us at: www.gaeyepartners.com.
About Nova Eye Medical
Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include the iTrack™ portfolio of canaloplasty devices for the treatment of glaucoma. The Company also manufactures and sells the proprietary Molteno3® glaucoma drainage device for the treatment of severe or complex glaucoma. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.
Contacts
Jules Lydon
(404) 383-0868
julianna.lydon@eyesouthpartners.com
Presenting a New Innovation in the Field of Spinal Rehabilitation at Physiowell DubaiDUBAI, ARAB EMIRATES…
SINGAPORE, June 23, 2024 /PRNewswire/ -- Singapore-headquartered Juniper Biologics Pte Ltd (Juniper), a leading healthcare…
FRONTIER2 data presented at ISTH 2024 showed that up to 95% of people, who had…
Pemvidutide elicited significant weight loss and decreases in pro-inflammatory serum lipids associated with atherogenesis and…
TAIPEI, June 22, 2024 /PRNewswire/ -- The prestigious 2024 Tang Prize Laureates have been announced,…
Afrezza® Afrezza® (insulin human) Inhalation Powder. Study proves inhaled insulin is as effective as usual…